Despite lacking a specific brand or generic name in the record, AUROBINDO PHARMA LTD is positioned for incremental revenue following the September 17, 2026, FDA approval of its ANDA application. Market observers will be watching for the brand-to-generic market share that the company captures as a result of this regulatory milestone.